Safety concerns mount over Neurocrine rare disease drug

Patient advocates and experts are raising alarm over safety issues tied to Neurocrine Biosciences' rare disease drug. The specific drug and adverse events are not detailed, but growing concern suggests potential regulatory or commercial impact. This is an emerging claim based on advocacy and expert opinion, not yet corroborated by regulatory action.